Tvardi Therapeutics, Inc.
TVRD Nasdaq
SEC CIK 1346830
Follow Tvardi Therapeutics
Weekly email: filings, results
Net income
−$6.1M
−10.8% vs same quarter last year
EPS, diluted
−$0.48
+18.6% vs same quarter last year
Operating cash flow
−$6.4M
−49.9% vs same quarter last year
Operating income
−$6.3M
−6.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$18.2M |
| FY24 | $7.1M | −$29.4M |
| FY23 | $21M | −$11.9M |
| FY22 | $41.9M | −$85.5M |
| FY21 | $23M | −$88.4M |
| FY20 | $135.1M | $8.4M |
| FY19 | $19.9M | −$106.4M |
| FY18 | $13.5M | −$74M |
| FY17 | $911K | −$58.1M |
| FY16 | $86K | −$57.3M |
| FY15 | $3.8M | −$24.7M |
| FY14 | $3.2M | −$17.7M |
| FY13 | $12M | −$4M |
| FY12 | $1.2M | −$6.3M |
| FY11 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | −393.8% | −411.9% |
| FY23 | −579.4% | −56.5% |
| FY22 | −209.1% | −204.2% |
| FY21 | −386.8% | −384.1% |
| FY20 | 4% | 6.2% |
| FY19 | −561.6% | −534.9% |
| FY18 | −574.5% | −549.5% |
| FY17 | −6529.6% | −6380.4% |
| FY16 | −67907% | −66604.7% |
| FY15 | −662.3% | −649.2% |
| FY14 | −568.8% | −558.5% |
| FY13 | −2% | −33.1% |
| FY12 | −524% | −527% |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$19.4M |
| FY23 | −$94.5M |
| FY22 | −$78.8M |
| FY21 | −$60.1M |
| FY20 | −$5.8M |
| FY19 | −$109.2M |
| FY18 | −$22.4M |
| FY17 | −$54.9M |
| FY16 | −$48.1M |
| FY15 | −$21.5M |
| FY14 | −$17.7M |
| FY13 | $2.8M |
| FY12 | - |
| FY11 | - |
- Tvardi Therapeutics
- Healthcare median
Show the numbers
| Year | Tvardi Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | −411.9% | −47% |
| FY23 | −56.5% | −58% |
| FY22 | −204.2% | −80.4% |
| FY21 | −384.1% | −71.8% |
| FY20 | 6.2% | −62.2% |
| FY19 | −534.9% | −46.2% |
| FY18 | −549.5% | −49.6% |
| FY17 | −6380.4% | −45.9% |
| FY16 | −66604.7% | −36% |
| FY15 | −649.2% | −37.8% |
| FY14 | −558.5% | −35.5% |
| FY13 | −33.1% | −37.1% |
| FY12 | −527% | −29.1% |
| FY11 | - | −27.9% |